1-(4-methoxynaphthalen-1-yl)propan-2-one | 16820-61-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-(4-methoxynaphthalen-1-yl)propan-2-one
• CAS: 16820-61-4
• 化学式: C₁₄H₁₄O₂
• 分子量: 214.264
• InChiKey: RZEJLTGNNNLYTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-methoxynaphthalen-1-yl)propan-2-one 、 苄胺 在 甲醇 、 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 4.0h， 以36%的产率得到rac-N-benzyl-1-(4-methoxynaphth-1-yl)propan-2-amine
  参考文献：
  名称：

  [EN] TRNA SYNTHETASE INHIBITORS
  [FR] INHIBITEURS D'ARNT SYNTHÉTASE

  摘要：

  本文披露了一种抑制tRNA合成酶的二级胺化合物。本发明的化合物在抑制革兰氏阴性细菌中的tRNA合成酶方面是有用的，并且在杀灭革兰氏阴性细菌方面也是有用的。本发明的二级胺化合物还在结核病的治疗中是有用的。

  公开号：

  WO2019140265A1
• 作为产物：
  描述：

  (4-甲氧基萘-1-基)-乙酸 、 乙酸酐 在 吡啶 作用下， 反应 6.0h， 以31%的产率得到1-(4-methoxynaphthalen-1-yl)propan-2-one
  参考文献：
  名称：

  Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective β2-adrenergic receptor agonists

  摘要：

  Purpose: To use a previously developed CoMFA model to design a series of new structures of high selectivity and efficacy towards the beta(2)-adrenergic receptor. Results: Out of 21 computationally designed structures 6 compounds were synthesized and characterized for beta(2)-AR binding affinities, subtype selectivities and functional activities. Conclusion: the best compound is (R,R)-4-methoxy-1-naphthylfelnoterol with K-i beta(2)-AR = 0.28 mu m, K-i beta(1)-AR/K-i beta(2)-AR = 573, EC50cAMP = 3.9 nm, EC50cardio = 16 nm. The CoMFA model appears to be an effective predictor of the cardiomocyte contractility of the studied compounds which are targeted for use in congestive heart failure. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.11.062

文献信息

• [EN] TRNA SYNTHETASE INHIBITORS<br/>[FR] INHIBITEURS D'ARNT SYNTHÉTASE
  申请人：HARVARD COLLEGE

  公开号：WO2019140265A1

  公开（公告）日：2019-07-18

  Disclosed herein are secondary amine compounds that inhibit tRNA synthetase. The compounds of the invention are useful in inhibiting tRNA synthetase in Gram-negative bacteria and are useful in killing Gram-negative bacteria. The secondary amine compounds of the invention are also useful in the treatment of tuberculosis.

  本文披露了一种抑制tRNA合成酶的二级胺化合物。本发明的化合物在抑制革兰氏阴性细菌中的tRNA合成酶方面是有用的，并且在杀灭革兰氏阴性细菌方面也是有用的。本发明的二级胺化合物还在结核病的治疗中是有用的。
• New derivatives of an aminoketone
  申请人：NIPPON KAYAKU KABUSHIKI KAISHA

  公开号：EP0200942A2

  公开（公告）日：1986-11-12

  A new aminoketone derivative having a central muscle relaxant activity which is represented by the following general formula: wherein R1 and are the groups defined as I, II or III below, one of R2 and R3 is a hydrogen atom and the other is a lower alkyl group; n is 0 when R1 is I or II, and it is 0 or 1 when R1 is III: I: R1 is a group selected from the groups ① to ⑦ mentioned below and ① a group of the formula ② a group of the formula (wherein R5 is a fluorine atom, a bromine atom, a lower alkoxyl group, a lower alkyl group, hydroxyl group, CH2=CH-, a phenyl group or ③ a group of the formula (wherein R6 is a halogen atom, a lower alkyl group, (wherein R4 is a trihalogenomethyl group), CH2=CH- or phenyl group), (Continuation next page) ④ a group of the formula (wherein both R7 and R8 each are halogen atoms, lower alkyl groups, lower alkoxyl groups or hydrogen atoms), ⑤ a group of the formula (wherein R9 and R10 each are halogen atoms, lower alkyl groups or lower alkoxyl group, and R10 is a substituent at the position 4 or 5 of the phenyl ring), ⑥ a group of the formula (wherein R9 is a lower alkoxyl group, a lower alkyl group or a halogen atom; R" is a substituent at the position 2 or 3 of the phenyl ring, and is a lower alkyl group, a lower alkoxyl group or a hydroxyl group; and R12 is a substituent at the position 5 or 6 of the phenyl ring, and is a lower alkyl group or a halogen atom), and ⑦ a group of the formula (wherein R9 is a lower alkoxyl group, a lower alkyl group or a halogen atom; R13 is a lower alkyl group, a lower alkoxyl group or a hydroxyl group; and R14 is a lower alkyl group or a lower alkoxyl group, provided that R14 is a lower alkoxyl group when R9 is a lower alkoxyl group at the position 4 of the phenyl ring): II: R' is a group selected from the groups ① or ② mentioned below and ① a group of the formula (wherein R15 and R16 each are lower alkyl groups or lower alkoxyl groups; and R" is a hydrogen atom or a lower alkoxyl group, provided that one of R15 and R16 is a lower alkoxyl group when R17 is a lower alkoxyl group), ② a group of the formula (wherein R'6 and R16 each are lower alkyl groups or lower alkoxyl groups and R18 is a lower alkyl group, provided that R'6 is a substituent at the position 3 or 4): III: R1 is a group selected from the groups ①,②,③ or ④ mentioned below and is a group of the formula ① a group of the formula (wherein R20 is a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxyl group), a group of the formula (wherein R21 is a halogen atom, a lower alkyl group or a lower alkoxyl group), ③ a group of the formula (wherein R22 is a lower alkoxyl group), and ④ a group of the formula (wherein R23 is a halogen atom or a lower alkyl group, R24 and R25 each are lower alkyl groups, and R26 is a lower alkyl group or a lower alkoxyl group), its pharmaceuticatly acceptable salt and a process for manufacturing thereof.

  一种具有中枢性肌肉松弛活性的新型氨基酮衍生物，其通式如下： 其中 R1 和 是下面定义为Ⅰ、Ⅱ或Ⅲ的基团，R2和R3中的一个是氢原子，另一个是低级烷基；当R1是Ⅰ或Ⅱ时，n为0，当R1是Ⅲ时，n为0或1：Ⅰ：R1 是选自下述基团①至⑦的基团，且 式中的一个基团 式中的一个基团 (其中 R5 是氟原子、溴原子、低级烷氧基、低级烷基、羟基、CH2=CH-、苯基或 式中的一个基团 (其中 R6 为卤素原子、低级烷基、 (其中 R4 为三卤代甲基）、CH2=CH- 或苯基），（下页接上文） 式中的一个基团 (其中 R7 和 R8 各为卤素原子、低级烷基、低级烷氧基或氢原子）、 式中的一个基团 (其中 R9 和 R10 各为卤素原子、低级烷基或低级烷氧基，且 R10 是位于苯环第 4 或第 5 位的取代基）、 式中的一个基团 (其中 R9 是低级烷氧基、低级烷基或卤素原子；R "是位于苯环第 2 或第 3 位的取代基，并且是低级烷基、低级烷氧基或羟基；R12 是位于苯环第 5 或第 6 位的取代基，并且是低级烷基或卤素原子），以及 ⑦ 式中的基团 式中的一个基团 (其中 R9 是低级烷氧基、低级烷基或卤原子；R13 是低级烷基、低级烷氧基或羟基；R14 是低级烷基或低级烷氧基，条件是当 R9 是位于苯环第 4 位的低级烷氧基时，R14 是低级烷氧基）： II：R'是选自下述基团①或②的基团，且 式中的一个基团 (其中 R15 和 R16 各为低级烷基或低级烷氧基；R "为氢原子或低级烷氧基，条件是当 R17 为低级烷氧基时，R15 和 R16 中的一个为低级烷氧基）、 式中的一个基团 (其中 R'6 和 R16 均为低级烷基或低级烷氧基，R18 为低级烷基，条件是 R'6 是位于 3 或 4 位的取代基）： III：R1 是选自下述基团①、②、③或④的基团，且 是式 式中的一个基团 (其中 R20 是氢原子、卤素原子、低级烷基或低级烷氧基、 低级烷基或低级烷氧基）、 式中的一个基团 (其中 R21 为卤素原子、低级烷基或低级烷氧基）、 式中的一个基团 (其中 R22 为低级烷氧基），以及 式中的一个基团 (其中 R23 为卤原子或低级烷基，R24 和 R25 分别为低级烷基，R26 为低级烷基或低级烷氧基）的基团、其药学上可接受的盐及其制造方法。
• TRNA synthetase inhibitors
  申请人：President and Fellows of Harvard College

  公开号：US11261201B2

  公开（公告）日：2022-03-01

  Disclosed herein are secondary amine compounds that inhibit tRNA synthetase. The compounds of the invention are useful in inhibiting tRNA synthetase in Gram-negative bacteria and are useful in killing Gram-negative bacteria. The secondary amine compounds of the invention are also useful in the treatment of tuberculosis.

  本发明公开了抑制 tRNA 合成酶的仲胺化合物。本发明的化合物可用于抑制革兰氏阴性细菌中的 tRNA 合成酶，并可用于杀死革兰氏阴性细菌。本发明的仲胺化合物还可用于治疗结核病。
• TRNA SYNTHETASE INHIBITORS
  申请人：President and Fellows of Harvard College

  公开号：US20210053997A1

  公开（公告）日：2021-02-25

  Disclosed herein are secondary amine compounds that inhibit tRNA synthetase. The compounds of the invention are useful in inhibiting tRNA synthetase in Gram-negative bacteria and are useful in killing Gram-negative bacteria. The secondary amine compounds of the invention are also useful in the treatment of tuberculosis.
• Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective β2-adrenergic receptor agonists
  作者：Krzysztof Jozwiak、Anthony Yiu-Ho Woo、Mary J. Tanga、Lawrence Toll、Lucita Jimenez、Joseph A. Kozocas、Anita Plazinska、Rui-Ping Xiao、Irving W. Wainer

  DOI：10.1016/j.bmc.2009.11.062

  日期：2010.1

  Purpose: To use a previously developed CoMFA model to design a series of new structures of high selectivity and efficacy towards the beta(2)-adrenergic receptor. Results: Out of 21 computationally designed structures 6 compounds were synthesized and characterized for beta(2)-AR binding affinities, subtype selectivities and functional activities. Conclusion: the best compound is (R,R)-4-methoxy-1-naphthylfelnoterol with K-i beta(2)-AR = 0.28 mu m, K-i beta(1)-AR/K-i beta(2)-AR = 573, EC50cAMP = 3.9 nm, EC50cardio = 16 nm. The CoMFA model appears to be an effective predictor of the cardiomocyte contractility of the studied compounds which are targeted for use in congestive heart failure. (C) 2009 Elsevier Ltd. All rights reserved.